PKM and neoplasm: Pyruvate kinase isoform M2 (PKM2), the last rate‐limiting enzyme and driver of gastrointestinal cancer, promotes hepatic cancer progression by inducing an immunosuppressive microenvironment,46 and the inhibition of PKM2 suppresses PD‐L1 expression on tumor cells.47